As the American Psychiatric Association committees begin formal work on DSM-V, we welcomebrief editorials on issues that should be considered in its formulation. Issues for DSM-V: Should Obesity Be Included Obesity (body mass index >30), has increased significantly over the past 30 years(approximately 50% per decade) (1), afflicting 32.2% of adults in the United States (2). Obesity increase
DRUGS AND MEDICATIONS
Determining the Equine Drugs and Medications Designation for Each
Breed or Discipline.
Responsibility and Accountability of Trainers.
Equine Drugs and Medications Testing in Connection with an Appeal
Results, Confirmatory Analysis, and Retest.
Interpretations of the Federation Equine Drugs and Medications
Chapter and its Application to Particular Substances.
Equine Drugs and Medications, The No Foreign Substance Provisions.
Equine Drugs and Medications, The Therapeutic Substance Provisions.
Conditions For Therapeutic Administrations of Forbidden Substances.
Human Drug Testing.
DRUGS AND MEDICATIONS
GR401-408. Equine Drugs and Medications Provisions Applicable to All Breeds and/orDisciplines.
Determining the Equine Drugs and Medications Designation for Each Breed
The Board of Directors shall designate every Breed, Discipline, and/or Group competing under Federation Rules as either a No Foreign Substance Group or aTherapeutic Substance Group, as outlined herein below.
At each Annual Meeting, each Division Committee shall determine by a majority vote and shall indicate to the Board of Directors its preference for its Breed or Discipline to bedesignated as (or to be part of) either a No Foreign Substance Group or a TherapeuticSubstance Group. In any instance where more than one Division Committee is responsiblefor a Breed and/or Discipline Group, after each committee has determined its preference bya majority vote, unanimity between and/or among the Division Committees of the Group shall be required to invoke a recommendation to be designated a No Foreign SubstanceGroup. Absent such concurrence, the joint recommendation of the Division Committees ofthe Group shall be construed as a recommendation in favor of designation as a TherapeuticSubstance Group. Each Division Committee shall have responsibility to recommend for its division. At its final meeting of the Rule Change Convention, the Board shall take into consideration these recommendations and the written recommendations of the respectiveAffiliate Associations in this regard, and it shall enact the designation for each Breed,Discipline, and/or Group. The effective dates of these designations shall coincide with theeffective dates of the newly published Rule Book.
These designations shall be reviewed by each Division Committee at the subsequent Every horse and/or pony competing at Federation competitions and/or events shall be subject to either the No Foreign Substance Provisions (GR409) or the TherapeuticSubstance Provisions (GR410-412), depending upon its Breed’s, Discipline’s, and/orGroup’s designation, and it shall be required to compete in compliance therewith, whethercompeting in unrated or rated classes and/or divisions.
Any horse and/or pony that competes in more than one Breed, Discipline, and/or Group at a competition, one of which is a No Foreign Substance Group, shall be required to be incompliance with the No Foreign Substance Provisions at all times while competing in anyand/or all classes and/or divisions at that competition.
Horses and/or ponies competing at a Licensed Competition are subject to examination by a licensed veterinarian who must be appointed by the Administrator of the Equine Drugsand Medications Program. Said appointed veterinarian, with the approval of theAdministrator, may appoint a technician to perform certain duties under this Rule. Theexamination may include physical, urine, blood tests and/or any other test or procedure atthe discretion of said veterinarian necessary to effectuate the purposes of this rule. Saidveterinarian may examine any or all horses and/or ponies in a class or all classes in acompetition or any horses and/or ponies entered in any class, whether in competition or not,if on the competition grounds, or any horse and/or pony withdrawn by any exhibitor within24 hours prior to a class for which it has been entered. 2.
Whether a horse and/or pony is in competition or not, refusal to submit the horse and/or pony for examination or to cooperate with the veterinarian or his agents constitutes aviolation and subjects the responsible person to penalties under GR406.
Trainers who are not able to accompany Federation drug testing personnel and the horse and/or pony to the location where sample collection is to take place, to act as witnessto the collection and sealing of blood and urine samples, and to sign the drug collectiondocuments in the appropriate places as witness, must appoint an agent to do so. Theabsence of such a witness shall constitute a waiver of any objection to the identification ofthe horse and/or pony tested and the manner of collection and sealing of the samples. Upon the collection of a sufficient number of tubes of blood from the horse or pony, the tubes shall be divided into two groups. One group shall be labeled and identified as BloodSample A and the other as Blood Sample B, and they shall be sealed accordingly. Upon thecollection of a sufficient volume of urine from the horse or pony, a portion of the sampleshall be poured into a second urine sample container. One container shall be labeled andidentified as Urine Sample A and the other as Urine Sample B, and they shall be sealedaccordingly. These procedures shall be performed whether or not the trainer or his/herappointed witness is present as provided for in Section 3 above. 5.
In the event reasonable attempts at sample collections from the horse or pony do not provide a sufficient number of tubes of blood or a sufficient volume of urine to be divided,labeled, and identified as Samples A and B, as determined by the testing veterinarian and/ortechnician, the sample(s) obtained (if obtained) shall be labeled and identified as Sample(s)A only, and it shall be recorded in the records of the Equine Drugs and Medications DRUGS AND
Program that the corresponding Sample(s) B does (do) not exist, in which event theobtained Sample(s) shall be subject to testing. Cooperation.
Cooperation with the veterinarian and/or his agent(s) includes:a. Taking the horse and/or pony and the veterinarian and/or his agent(s) immediatelyto the location selected by said veterinarian and/or agent(s) for testing the horse and/or pony and presenting it for testing.
b. Assisting the veterinarian and/or his agent(s) in procuring the sample promptly,including but not limited to removing equipment from the horse and/or pony, leaving it quietly in the stall and avoiding any distractions to it. Schooling, lengthy cooling out,bandaging and other delays of this type shall be construed as noncooperation.
c. Polite attitude and actions toward the veterinarian and/or his agent(s).
Responsibility and Accountability of Trainers.
A trainer is defined as any adult or adults who has or shares the responsibility for the care, training, custody, condition, or performance of a horse and/or pony. Said person mustsign the entry blank of any Licensed Competition whether said person be a trainer, owner,rider, agent and/or coach. Where a minor exhibitor has no trainer, then a parent, guardian oragent or representative thereof must sign the entry blank and assume responsibility astrainer. The name of the trainer must be designated as such on the entry blank. It is theresponsibility of trainers as well as competition management to see that entry blankscontain all of the required information. 2.
Trainers in the absence of substantial evidence to the contrary are responsible and accountable under the penalty provisions of these rules: a. for the condition of a horse or pony at a Licensed Competition (whether or not theyhave signed an entry blank), b. to guard each horse and/or pony at, and sufficiently prior to, a Licensed Competitionsuch as to prevent the administration by anyone of, or its exposure to, any forbiddensubstance, and c. to know all of the provisions of this Chapter 4 (including any advisories orinterpretations published in equestrian) and all other rules and regulations of theFederation and the penalty provisions of said rules. For purposes of this rule,substantial evidence means affirmative evidence of such a clear and definite nature asto establish that said trainer, or any employee or agent of the trainer, was, in fact, notresponsible or accountable for the condition of the horse and/or pony. If any trainer isprevented from performing his or her duties, including responsibility for the condition ofthe horses and/or ponies in his or her care, by illness or other cause, or is absent fromany Licensed Competition where horses and/or ponies under his or her care areentered and stabled, he or she must immediately notify the competition secretary and,at the same time, a substitute must be appointed by the trainer and such substitutemust place his or her name on the entry blank forthwith. Such substitution does notrelieve the regular trainer of his/her responsibility and accountability under this rule;however, the substitute trainer is equally responsible and accountable for the conditionof such horses and/or ponies. The trainer and owner acknowledge that the trainer represents the owner regarding horses and/or ponies being trained or managed, entries, scratches for any reason and anyact performed on any horse and/or pony under the care and custody of the trainer.
In the case of a horse and/or pony competing under the Therapeutic Substance Provisions, any trainer or other person subject to these rules who actually administers,attempts to administer, instructs, aids, conspires with another to administer or employsanyone who administers or attempts to administer a forbidden substance to a horse and/orpony which might affect the performance of said horse and/or pony at a competitionlicensed by the Federation without complying with GR411, is subject to the penaltiesprovided in GR406. 5.
Any trainer or person subject to these rules who administers, attempts to administer, instructs, aids, conspires with another to administer or employs anyone who administers orattempts to administer any substance to a horse and/or pony by injection or by any otherroute of administration, whether the substance is forbidden or permitted, in the competitionring of a competition licensed by the Federation during a scheduled class, is subject to thepenalties provided in GR406.
Equine Drugs and Medications Testing in Connection with an Appeal
Each animal submitted for an appeal measurement is subject to the Drugs and Medications Chapter at the time of said measurement and/or concurrent examinations, and said animal must be in compliance therewith.
Each animal submitted for an appeal measurement must have drug testing samples collected at the time of said measurement and/or concurrent examinations. No sample is adrug testing sample unless it is collected by and/or under the direct supervision ofFederation drug testing personnel, who must be appointed by the Administrator of theEquine Drugs and Medications Program to collect samples from the animal in question in DRUGS AND
connection with said measurement.
Each animal submitted for an appeal measurement must have both a urine sample and a blood sample collected at the time of said measurement and/or concurrent examinations.
Both the urine sample and the blood sample must be of sufficient volume for drug testingpurposes, as determined by the Administrator of the Equine Drugs and MedicationsProgram. Said sample collections shall be conducted in accordance with procedures whichare the sole prerogative of the Federation drug testing personnel. As deemed necessary bythe Federation testing veterinarian, the animal shall be administered furosemide to cause itto produce a urine sample in a timely manner.
Every blood sample and/or urine sample collected in connection with an appeal measurement and all portions thereof are the sole property of the Federation. Said samplesand all portions thereof must remain in the sole custody of the Federation drug testingpersonnel at all times during said measurement and/or concurrent examinations, andsubsequently they must be submitted to the Federation’s laboratory for testing inaccordance with the instructions of the Administrator of the Equine Drugs and MedicationsProgram.
The entire cost of sample collections and testing conducted in connection with an appeal measurement, including the fees and expenses of Federation drug testingpersonnel, shipping costs for equipment and samples, laboratory charges, etc., asdetermined by the Administrator of the Equine Drugs and Medications Program, must bepaid in full by the appellant within 30 days of the submission of an invoice, regardless of theoutcome of said measurement, and regardless of the laboratory results. A deposit in cash orcertified check equal to the costs of sampling and testing, as estimated by the Administratorof the Equine Drugs and Medications Program, may be required prior to the measurement.
No appeal measurement is valid absent written affirmation of the CEO or Executive Director confirming the receipt of negative drug testing results from the Federation’slaboratory, indicating that both the urine and blood sample collected from the animal inquestion in connection with said measurement and/or concurrent examinations were found tocontain no forbidden substance, said results having been issued to the Administrator of theEquine Drugs and Medications Program. Any instance involving a finding of forbiddensubstance shall additionally result in the issuance of a charge of violation of Chapter 4 foradjudication by the Hearing Committee in accordance with the provisions of Chapters 6 and 7.
Results, Confirmatory Analysis, and Retest.
Blood and urine samples labeled and identified as Samples A shall be subjected to chemical analysis by the Federation Drug Testing Laboratory or by a laboratory with whichFederation has contracted for its services. Blood and urine samples labeled and identifiedas Samples B shall be stored securely, unopened, at the Federation Drug TestingLaboratory, to be used in the event that a confirmatory analysis shall be required. 2.
In the event the chemical analysis of Blood or Urine Sample A is negative, i.e., no forbidden substance or any metabolite or analogue thereof is found to be present in thesample, the corresponding Blood or Urine Sample B shall be destroyed by the laboratory. 3.
In the event the chemical analysis of Blood or Urine Sample A is positive, i.e., a forbidden substance or any metabolite or analogue thereof is found to be present in thesample, this shall be prima facie evidence that the forbidden substance was administered insome manner to said horse or pony, whether intentionally or unintentionally, or otherwise DRUGS AND
was caused to be present in the tissues, body fluids or excreta of the horse or pony at thecompetition, whether intentionally or unintentionally, such that the trainer(s) deemedresponsible and accountable for its condition is (are) liable under the provisions of GR404. 4.
In the event the chemical analysis of Blood or Urine Sample A is positive, and upon the issuance of Notices of Charge to persons deemed responsible and accountable under therules, a person charged who requests a confirmatory analysis of the corresponding Blood or Urine Sample B must make the request in writing to Counsel of the Equine Drugs andMedications Committee, and it must be received within 15 days of the date of the Notice ofCharge. 5.
The confirmatory analysis of the corresponding Blood or Urine Sample B shall be performed by a drug testing laboratory that must be mutually agreed upon by the personcharged who requests the confirmatory analysis and Counsel of the Equine Drugs andMedications Committee, which laboratory must have demonstrated proficiency inperforming the necessary confirmatory analysis, provided the corresponding Blood or UrineSample B exists and is of sufficient volume to permit a confirmatory analysis. In the eventthe drug testing laboratory that analyzed Sample A is the only laboratory that hasdemonstrated proficiency in performing the necessary confirmatory analysis, as determinedby Counsel of the Equine Drugs and Medications Committee, this laboratory shall be theonly laboratory to which Counsel of the Equine Drugs and Medications Committee shallagree to perform the confirmatory analysis of the corresponding Sample B. Upon thecompletion of the confirmatory analysis, the laboratory performing the confirmatory analysisshall forward its findings and supporting data to all parties. 6.
In the event no agreement is reached as to a laboratory as required in section 5 above, and the person charged who requests the confirmatory analysis does not revoke his/herrequest, the confirmatory analysis of the corresponding Blood or Urine Sample B shall beperformed by the Federation Drug Testing Laboratory, or by a laboratory with which TheFederation has contracted for its services, as determined by Counsel of the Equine Drugsand Medications Committee, which laboratory shall forward its findings and supporting datato all parties. Both the results of the analysis of Sample A (and supporting data) and theresults of the confirmatory analysis of the corresponding Sample B, if any (and supportingdata, if any), shall be admissible as evidence in any hearing or proceeding pertaining to thismatter. 7.
In the event the corresponding Blood or Urine Sample B does not exist, or is of insufficient volume to permit a confirmatory analysis, as determined by Counsel of theEquine Drugs and Medications Committee, and there exists a remaining aliquot of Blood orUrine Sample A which is of sufficient volume to permit a retest, as determined by Counsel ofthe Equine Drugs and Medications Committee, a person charged who requests the retest ofBlood or Urine Sample A must make the request in writing to Counsel of the Equine Drugsand Medications Committee, and it must be received within 7 days of the determination thatthe corresponding Blood or Urine Sample B does not exist or is of insufficient volume topermit a confirmatory analysis. 8.
Any requested re-test of the remaining aliquot of Blood or Urine Sample A, provided it is of sufficient volume to permit a retest, shall be performed by the Federation Drug TestingLaboratory, or by a laboratory with which The Federation has contracted for its services, asdetermined by Counsel of the Equine Drugs and Medications Committee.
The retest of the remaining aliquot of Blood or Urine Sample A may be witnessed by a Witnessing Analyst appointed by the person charged who requests such analysis at thesame time as the retest is requested. The Witnessing Analyst must be a qualified analyticalchemist employed by an equine drug testing laboratory. If no Witnessing Analyst isappointed by the person requesting the retest, or if the Witnessing Analyst is unavailablewithin a reasonable time, the requested retest of the remaining aliquot of Blood or UrineSample A shall proceed without the Witnessing Analyst. 10. In the event the Witnessing Analyst appointed by the person requesting the retest of theremaining aliquot of Blood or Urine Sample A is satisfied that the positive result is correct,Counsel of the Equine Drugs and Medications Committee must be informed immediately byfax with confirmation by letter. 11. In the event the Witnessing Analyst is not satisfied that the result of the retest of theremaining aliquot of Blood or Urine Sample A is correct, Counsel of the Equine Drugs andMedications Committee must be informed immediately by fax followed by a written reportsetting forth the basis for the Witnessing Analyst’s opinion. Copies of the original andsubsequent results and supporting analytical data must be submitted to the FederationHearing Committee as part of the hearing record in the case, for resolution by it of any and all issues regarding the original analysis of Blood or Urine Sample A and the retest of theremaining aliquot of Blood or Urine Sample A. 12. By requesting the confirmatory analysis of the corresponding Blood or Urine Sample B,or the retest of the remaining aliquot of Blood or Urine Sample A, or by requesting that the retest be witnessed by a Witnessing Analyst, the person charged who makes suchrequest(s) agrees to and must pay any and all fees, costs and expenses relating to theconfirmatory analysis or the retest, whether it is performed by a mutually agreed uponlaboratory, by the Federation Drug Testing Laboratory, or by a laboratory with which TheFederation has contracted for its services, upon the presentation an invoice by Counsel ofthe Equine Drugs and Medications Committee, and any and all fees, costs, and expenses DRUGS AND
relating to the Witnessing Analyst. 13. In the case of a horse and/or pony competing under the Therapeutic SubstanceProvisions, if the chemical analysis of the sample taken from such horse and/or ponyindicates the presence of a forbidden substance or any metabolite or analogue thereof andall the requirements of GR411 have been fully complied with, the information contained insaid Equine Drugs and Medications Report Form and any other relevant evidence will beconsidered by the Federation in determining whether a rule violation was committed by anyperson(s) responsible or accountable for the condition of the horse and/or pony under theprovisions of this rule.
14. When a positive report is received from the chemist identifying a forbidden substance,or any metabolite or analogue thereof, a hearing will be held in accordance with Chapter 6,except as may otherwise be provided by GR412. No trainer, responsible or accountable forthe condition of said horse and/or pony, will be suspended, or a horse and/or pony barredfrom competition, until after an administrative penalty has been assessed or after theconclusion of a hearing and a written ruling thereon has been made.
15. The owner or owners of a horse and/or pony found to contain a forbidden substance orany metabolite or analogue thereof may be required to forfeit all prize money, sweepstakes,added money and any trophies, ribbons and “points” won at said competition by said horseand/or pony and the same will be redistributed accordingly. The owner must pay a fee of$300 to said competition. Points accumulated toward Horse of the Year Awards prior to saidcompetition may be nullified and redistributed at the discretion of the Hearing Committee. If,prior to or at a hearing, the Federation as the charging party, determines that one or morepersons, not previously charged as a trainer should also be charged as a trainer, then, uponapplication by the Federation, the Hearing Committee may, in its discretion, continue oradjourn the hearing, in whole or in part, to permit a new or amended charge to be issued(unless the person(s) to be charged waive notice). 16. A trainer of a horse and/or pony found to contain such forbidden substance or anymetabolite or analogue thereof is subject to whatever penalty is assessed by the HearingCommittee, except for administrative penalties issued by the Chairman of the Equine Drugsand Medications Committee and accepted, as provided by GR412. Said trainer may befined and may be suspended from all participation in Licensed Competitions for a period of one year for the first offense, and for a longer period for a second or later offense, saidsuspension to be served at any time at the discretion of the Hearing Committee.
The horse and/or pony may be suspended for any period of time specified by the HearingCommittee. In determining an appropriate penalty under these rules, the HearingCommittee may take into account such factors and circumstances as it may deem relevant,including but not limited to a. the pharmacology of the forbidden substance, b. the credibility and good faith of the person charged or of other witnesses, c. penalties determined in similar cases, andd. past violations of any Federation rules (or the lack thereof). e. reliance upon the professional ability or advice of a veterinarian who is a licensedgraduate of an accredited veterinary school and who is in good standing in the state inwhich he/she primarily practices. DRUGS AND
17. If the Hearing Committee determines that any violation or attempted violation of thisRule was willful and/or intentional, there shall not be any limit to the period of a suspension,and the Hearing Committee may impose other and significantly greater penalties than itwould have in the absence of such a determination. Management Procedures.
To provide funds for research, inspection and enforcement of rules regarding use of medications and drugs, each Licensed Competition, except where prohibited by law, mustassess the exhibitors a fee of $7 for each horse and/or pony entered in the competition,except the fee shall be $15 for each horse entered in an FEI sanctioned competition or a USEF High Cap Computer List Class. Participants in the following classes are exemptedfrom payment: a. leadline b. exhibitions c. games and races,d. classes for 4-H members, e. Academy classes (Academy classes are classes limited to horses used regularly ina lesson program) f.
However, these classes are not exempt from the Drugs and Medications Chapter itself.
Within 10 days after a competition, competition management must forward to theFederation a sum representing the above fee times the number of horses and/or poniesentered in the nonexempt classes of the competition plus the number of horses and/orponies scratched where the fee is not refunded, such sum to be held by the Federation in aseparate fund for use to accomplish the purpose set forth above. 2.
It is a violation for a Licensee to assess and/or collect a drug enforcement fee in excess of or in addition to that specified and required by GR407.1 of these rules, unless saidassessment is approved in writing by the Federation in advance, and then only under theterms and conditions set forth. 3.
It is a violation for a Licensee to withhold from the Federation any or all of the drug fees collected in accordance with GR407.1, for any purpose, including to defray the expensesincurred providing stalls, passes, and other items to the Federation drug testing personnel,as required by GR407.4 and .5. 4.
Each Licensed Competition shall, at its own cost and expense, set aside and make available to The Federation testing personnel upon request suitable facilities convenientlylocated for the veterinarian appointed by the Federation and his or her technicians to collectequine blood and urine samples. Suitable facilities means one or more stalls if available, asrequested, that are well lit, clean, dry, freshly bedded, and having a door or gate that can besecured. 5.
Each Licensed Competition, upon request, must furnish the veterinarian appointed by The Federation and/or the Administrator of the Equine Drugs and Medications Program bymail forthwith, with the requested number of official passes and parking passes for theveterinarians and technicians to have immediate and free access to all areas at saidLicensed Competition. 6.
Competition management must cooperate with and exhibit polite attitude and actions toward the veterinarian and/or his agents.
Interpretations of the Federation Equine Drugs and Medications Chapter
and its Application to Particular Substances.
Any questions regarding the interpretation of this Chapter, including the application of thisChapter to particular substances, should be directed to the office of the Federation EquineDrugs and Medications Program, 956 King Avenue, Columbus, Ohio 43212-2655. (800)633-2472, (614) 299-7707, FAX (614) 299-7706. Trainers and/or owners who seek adviceconcerning the interpretation and application of this rule should not rely solely uponinterpretations or advice by private or competition veterinarians, competition officials,competition personnel, or other persons, but should also obtain verification of any suchinterpretations or advice from the Federation Equine Drugs and Medications Program office.
Any trainer or owner who is uncertain about whether this rule applies in any given situationwould be well advised to withdraw the affected horse and/or pony from competition untilsuch time as the Federation Equine Drugs and Medications Program office has beenconsulted.
Equine Drugs and Medications,
The No Foreign Substance Provisions.
No horse and/or pony competing in a Breed or Discipline designated as (or part of) a No Foreign Substance Group is to be shown in any class at a competition licensed by theFederation if it has been administered in any manner or otherwise contained in its tissues,body fluids or excreta a prohibited substance as defined in this Rule. For purposes of this Rule, a prohibited substance shall be as defined by the pertinent Regulations and Annexesof the Federation Equestre Internationale (FEI). 2.
EXHIBITORS, OWNERS, TRAINERS, AND VETERINARIANS ARE CAUTIONED AGAINST THE USE OF MEDICINAL PREPARATIONS, TONICS, PASTES, ANDPRODUCTS OF ANY KIND, THE INGREDIENTS AND QUANTITATIVE ANALYSIS OFWHICH ARE NOT SPECIFICALLY KNOWN, AS MANY OF THEM NO DOUBT CONTAIN DRUGS AND
Equine Drugs and Medications,
The Therapeutic Substance Provisions.
No horse and/or pony competing in a Breed or Discipline designated as (or part of) a Therapeutic Substance Group is to be shown in any class at a competition licensed by theFederation (see also GR402.1, last sentence) if it has been administered in any manner orotherwise contains in its tissues, body fluids or excreta a forbidden substance except asprovided in GR411. Any horse and/or pony that competes in more than one Breed,Discipline, and/or Group at a competition, one of which is a No Foreign Substance Group,shall be required to be in compliance with the No Foreign Substance Provisions at all timeswhile competing in any and/or all classes and/or divisions at that competition. For purposesof this rule, a forbidden substance is: a. Any stimulant, depressant, tranquilizer, local anesthetic, psychotropic (mood and/orbehavior altering) substance, or drug which might affect the performance of a horseand/or pony (stimulants and/or depressants are defined as substances which stimulateor depress the cardiovascular, respiratory or central nervous systems), or anymetabolite and/or analogue of any such substance or drug, except as expresslypermitted by this rule.
b. Any corticosteroid present in the plasma of the horse/pony other thandexamethasone (see GR410.5b).
c. Any nonsteroidal anti-inflammatory drug in excess of two present in the plasma orurine of the horse/pony (GR411 does not apply); exception: salicylic acid.
d. Any substance (or metabolite and/or analogue thereof) permitted by this rule inexcess of the maximum limit or other restrictions prescribed herein.
e. Any substance (or metabolite and/or analogue thereof), regardless of how harmlessor innocuous it might be, which might interfere with the detection of any of thesubstances defined in (a), (b), (c) or (e) or quantification of substances permitted by thisrule.
Any anabolic steroid in the breeding/in-hand classes for three-year-olds and under in the Arabian, Half Arabian, and Anglo Arabian Division (GR411 below does not apply). EXHIBITORS, OWNERS, TRAINERS, AND VETERINARIANS ARE CAUTIONED AGAINST THE USE OF MEDICINAL PREPARATIONS, TONICS, PASTES, AND PRODUCTS OF ANY KIND, THE INGREDIENTS AND QUANTITATIVE ANALYSIS OFWHICH ARE NOT SPECIFICALLY KNOWN, AS MANY OF THEM MAY CONTAIN AFORBIDDEN SUBSTANCE.
The full use of modern therapeutic measures for the improvement and protection of the health of the horse and/or pony is permitted unless: a. The substance administered is a stimulant, depressant, tranquilizer, localanesthetic, drug or drug metabolite which might affect the performance of a horseand/or pony or might interfere with the detection of forbidden substances orquantification of permitted substances; orb. More than two nonsteroidal anti-inflammatory drugs are present in the plasma orurine of the horse/pony (GR411 does not apply); exception: salicylic acid; orc. The presence of such substance in the blood or urine sample exceeds themaximum limit or other restrictions prescribed herein below.
Restrictions concerning the nonsteroidal anti-inflammatory drugs are as follows:a. The maximum permitted plasma concentration of diclofenac is 0.005 microgramsper milliliter. b. The maximum permitted plasma concentration of phenylbutazone is 15.0micrograms per milliliter.
c. The maximum permitted plasma concentration of flunixin is 1.0 micrograms per milliliter.
d. The maximum permitted plasma concentration of ketoprofen is 0.250 microgramsper milliliter.
e. The maximum permitted plasma concentration of meclofenamic acid is 2.5 The maximum permitted plasma concentration of naproxen is 40.0 micrograms per milliliter.
g. The maximum permitted plasma concentration of firocoxib is 0.240 micrograms permilliliter.
h. Upon the approval of eltenac by the FDA, the maximum permitted plasmaconcentration of eltenac is 0.1 micrograms per milliliter. i.
Effective April 1, 2010 and through November 30, 2011, at which time only one of the substances listed in (a) through (f) above will be permitted, a maximum of twosubstances listed in (a) through (f) above are permitted to be present in the sameplasma or urine sample, only if both substances are reported on a Federation NSAIDDisclosure Form and filed with the competition prior to the horse competing (GR411does not apply). j.
Phenylbutazone and flunixin are not permitted to be present in the same plasma or urine sample (GR411 does not apply).
k. Any nonsteroidal anti-inflammatory drug not listed in (a) through (g) above isforbidden to be present in the plasma or urine sample (GR411 does not apply);exception: salicylic acid. l.
Any nonsteroidal anti-inflammatory drug that becomes approved for use in horses can be added to the list of those permitted, after the completion, review and approval ofthe needed research. Restrictions concerning other therapeutic substances are as follows:a. The maximum permissible plasma concentration of methocarbamol is 4.0micrograms per milliliter.
b. The maximum permitted plasma concentration of dexamethasone is 0.003micrograms per milliliter.
Thresholds for substances of possible dietary origin are as follows: a. The maximum permissible urine concentration of theobromine is 2.0 microgramsper milliliter.
Additional restrictions concerning particular classes and/or divisions (GR411 does not a. In the breeding/in-hand classes for three-year-olds and under in the Arabian, HalfArabian, and Anglo Arabian Division, any anabolic steroid is forbidden. (See HOWLONG DRUGS REMAIN DETECTABLE in the current Drugs and Medications RulesPamphlet for guidelines). Conditions For Therapeutic Administrations of Forbidden Substances.
A horse and/or pony exhibiting at a Licensed Competition pursuant to the Therapeutic Substance Provisions that receives any medication which contains a forbidden substance isnot eligible for competition unless all of the following requirements have been met and thefacts are furnished in writing on a timely-submitted official Equine Drugs and MedicationsReport Form: a. The medication must be therapeutic and necessary for the diagnosis or treatment ofan existing illness or injury. Administration of a forbidden substance for non-therapeuticor optional purposes (such as, by way of example only, shipping, clipping, training,turning out, routine floating or cleaning of teeth, non-diagnostic nerve blocking,uncasting, mane pulling or non-emergency shoeing) is not considered to betherapeutic. Any trainer who is uncertain about whether a particular purpose isconsidered to be therapeutic would be well advised to consult the Federation EquineDrugs and Medications Program office.
b. The horse and/or pony must be withdrawn from competition for a period of not lessthan 24 hours after the medication is administered.
c. The medication must be administered by a licensed veterinarian, or, if aveterinarian is unavailable, only by the trainer pursuant to the advice and direction of aveterinarian.
d. Identification of medication—the amount, strength and mode of administration.
e. Date and time of administration.
Identification of horse and/or pony, its name, age, sex, color and entry number.
g. Diagnosis and reason for administration.
h. Statement signed by person administering medication.
Equine Drugs and Medications Report Form filed with the Steward/Technical Delegate or Designated Competition Office Representative within one hour afteradministration or one hour after the Steward/Technical Delegate or Designated DRUGS AND
Competition Office Representative returns to duty if administration is at a time otherthan during competition hours. j.
The Steward, Technical Delegate, or Designated Competition Office Representative must sign and record the time of receipt on the Equine Drugs and Medications ReportForm. k. At selection trials for World Championships, and/or Olympic and/or Pan AmericanGames, the requirement of subsection (b) above, that the horse or pony must bewithdrawn from competition for a period of not less than 24 hours after the medication isadministered will not apply, provided that: (1) the competition is conducted pursuant to the written selection procedures asapproved by the Federation Executive Committee; (2) the written selection procedures specifically allow for therapeutic administrationsof medications by a USEF-appointed veterinary panel within 24 hours precedingcompetition, and the written selection procedures are in no case less stringent inthis regard than the FEI Veterinary Regulations (Articles 1006.7 and 1006.8) andguidelines pursuant thereto;(3) all requirements of the written selection procedures regarding therapeuticadministrations of medications have been met;(4) all requirements of this Rule have been met except subsection GR411.1(b); andall persons competing in the competition are eligible and competing for selection.
Where all the requirements of GR411 have been fully complied with, the information contained in said Equine Drugs and Medications Report Form and any other relevantevidence will be considered by the Federation in determining whether a rule violation wascommitted by any person(s) responsible or accountable for the condition of the horse and/orpony under the provisions of this rule.
NOTE: The official Equine Drugs and Medications Report Form is available from theofficiating Steward/Technical Delegate and/or Competition Secretary. All requiredinformation must be included when filing a report. Failure to satisfy and follow all therequirements of this Rule and to supply all of the information required by such Equine Drugsand Medications Report Form is a violation of the rules. The Steward/Technical Delegatemust report any known violations of this Rule to the Federation for such further action asmay be deemed appropriate.
The provisions for administrative penalties shall apply to any potential or alleged violation of the Equine Drugs and Medications Rule. The Federation shall hold in abeyancethe issuance of charges of rule violation pending further determination by the Chairman ofthe Equine Drugs and Medications Committee, who shall take into consideration allpertinent information available, including the seriousness of the alleged violation(s),precedents in similar Federation drug cases, and any prior rule violation(s) by theindividual(s). At all times while consideration is given as to a determination by the Chairmanof the Equine Drugs and Medications Committee, the identity of the horse, rider, trainer,coach, and owner must not be known or disclosed to him. EC 2/22/11 Effective immediately2.
The Chairman of the Equine Drugs and Medications Committee shall, upon consultation with staff, and within 60 days of receipt of laboratory results, make adetermination in his or her discretion whether to recommend the issuance of charges by the DRUGS AND
Federation, whether to recommend a plea agreement, whether to impose administrativepenalties, or whether to take no further action in the matter, and shall communicate thatdecision in writing to the Federation’s CEO or Executive Director. 3.
In the event the Chairman of the Equine Drugs and Medications Committee determines to impose administrative penalties in accordance with GR412.2, in lieu of arecommendation to issue charges, he or she shall be authorized to impose any or all of the penalties enumerated in Chapter 7, GR703, setting forth the terms and conditions forcompliance. The trainer(s) and owner(s) shall after receiving written notice of the right to ahearing, after their written waiver of same, and written acceptance of an administrativepenalty, be subject to any and all administrative penalties imposed by the Chairman of the Equine Drugs and Medications Committee. 4.
The Federation shall give written notification to trainer(s) and owner(s) of administrative penalties determined pursuant to GR412.3 above, the terms and conditions of which shallnot be subject to negotiation. An administrative penalty must be approved by the HearingCommittee Co-Chairs before it is offered to the Respondent(s). Once accepted by all partiesand by the Hearing Committee, an administrative penalty shall have the same force andeffect as would a finding of rule violation by the Hearing Committee following a hearingpursuant to Chapters 6 and 7, and will be published on the Federation’s web site. EC 6/20/11 Effective immediately5.
Any trainer(s), or owner(s), or both, who have received notice of an administrative penalty under GR412.4 and who have not accepted same in writing shall receive a hearingbefore the Hearing Committee, in accordance with Chapters 6 and 7. Administrativepenalties accepted in accordance with this Rule shall be effective immediately, shall befinal, and shall not be subject to further review under any circumstance(s).
In the event an administrative penalty is not accepted in writing, the Federation shall issue a written charge or charges pursuant to Chapter 6, and the Hearing Committee shallconduct a hearing pursuant to Chapters 6 and 7 upon said charge(s). In the event of afinding of a violation, the Hearing Committee shall not be limited in choice of penalties tothose that might have been imposed in accordance with GR412.2 and .3, nor in any suchinstance shall the Hearing Committee be limited in any other way in exercising all of itsprerogatives as set forth in the Bylaws and Rules.
Human Drug Testing
In accordance with the rules of the FEI and of the World Anti-Doping Agency (WADA), any Federation member shall comply with in-competition, no advance notice (NAN), andother out-of-competition drug testing conducted by the FEI, WADA, US Anti-Doping Agency(USADA) or by a WADA-authorized organization or USADA-authorized organization at anytime without advanced notice. Failure to cooperate with such in-competition, NAN or otherout-of-competition drug testing shall be a violation of Federation rules.
In conjunction with the above-described NAN or other out-of-competition drug testing, the Federation is required to submit the names, current addresses, telephone numbers,training times and training and competition locations for individuals and teams as requestedby the FEI, WADA, or USADA to enable FEI, WADA, or USADA to conduct NAN or otherout-of-competition drug testing. Notwithstanding the foregoing, compliance with anti-dopingregulations rests with the individual subject to testing.
A finding of violation of human drug rules by USADA or WADA shall be deemed a violation of Federation rules, and the reciprocity provisions of GR615.2 shall be applied. DRUGS AND
PREOPERATIVE INSTRUCTIONS AND INFORMATION ABOUT YOUR SURGICAL PROCEDURE I have scheduled you to have a growth excised in the office. Excision is themedical term for removal of a lesion from your skin. The wound is closedwith stitches (deep ones that dissolve in 2 months) and superficial ones thatare removed in 7-14 days. The goals of the procedure are complete removalof the growth and a